Connection
Joseph Saseen to Hyperlipoproteinemia Type II
This is a "connection" page, showing publications Joseph Saseen has written about Hyperlipoproteinemia Type II.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.077 |
|
|
|
-
Robinson JG, Jayanna MB, Brown AS, Aspry K, Orringer C, Gill EA, Goldberg A, Jones LK, Maki K, Dixon DL, Saseen JJ, Soffer D. Enhancing the value of PCSK9 monoclonal antibodies by identifying patients most likely to benefit. A consensus statement from the National Lipid Association. J Clin Lipidol. 2019 Jul - Aug; 13(4):525-537.
Score: 0.039
-
Braun LT, Saseen JJ, Orringer CE, Stone NJ, Guyton JR. JCL roundtable. The 2018 AHA/ACC/Multisociety Cholesterol Guidelines: Process and product. J Clin Lipidol. 2019 May - Jun; 13(3):345-355.
Score: 0.039